01 July 2005
Systemic effects of cancer: Role of multiple proteases and their toxic peptideproducts.
Harry RubinMed Sci Monit 2005; 11(7): RA221-228 :: ID: 16853
Abstract
Cachexia, or the loss of skeletal muscle, adipose tissue and immunologicalcompetence, is a common systemic condition in advanced cases of cancer, and is a frequent cause of death.There have been many reports that small peptides isolated from tumors induce systemic effects correlatedwith cachexia upon injection into mice or addition to cell cultures. Only recently has evidence beenpresented for the origin of these peptides from the large increase in proteolytic enzymes found in tumors.Additional evidence is presented here for a major role of tumor peptides in producing effects associatedwith cachexia. Such peptides of low molecular weight were found to produce lipolysis in adipose tissue.Fibrinogen degradation products from the plasma of cancer patients and other chronic diseases suppressactivation of the immune response. Some proteases of the cathepsin class occur in high concentrationat the surface of transformed cells where the pH is low enough to allow digestion of pericellular proteins;other cathepsins elevated in tumors are highly active at physiological pH. Cathepsin L is the major excretedprotein of cultured cells transformed by viruses or chemicals and is likely to form toxic peptides bydigestion of extracellular proteins. Even normal liver and skeletal muscle of some cancer patients andtumor-bearing animals exhibit significant increases in cathepsins and components of the ubiquitin-proteasesomepathway which would add to circulating peptides. These observations argue for a central role of multipleproteases and their proteolytic products in producing the debilitating systemic effects of cancer.
Keywords: Neoplasms - metabolism, Adipose Tissue - metabolism, Cachexia - metabolism, Cathepsins - metabolism, Fibrinogen - metabolism, Immune Tolerance, Lipolysis, Neoplasms - metabolism, Peptide Hydrolases - metabolism, Peptides - metabolism
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
18 Mar 2024 : Clinical Research
Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative StudyMed Sci Monit In Press; DOI: 10.12659/MSM.944136
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
Most Viewed Current Articles
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952